Morgan Stanley Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 83.2%

Neg 83.2% Neu 0% Pos 0%

Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $44 to $40.